Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead | ||
By: PR Newswire Association LLC. - 14 Feb 2024 | Back to overview list |
|
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead. An industry leader with more than 25 years of experience, Dr. Johnson-Pratt will guide therapeutic development for ANPD001, the first autologous neuron replacement to treat Parkinson's disease (PD), and new product strategy for Aspen. "We are delighted to welcome Dr. Johnson-Pratt to Aspen Neuroscience," said Damien McDevitt, PhD, Aspen Neuroscience president and chief executive officer. "As we prepare to enter the clinic with our first-in-human trial for Parkinson's disease, we are deepening our investment in the company's development. Lisa is a proven life cycle leader with a strong track record of advancing therapies through early and late-stage development to support compelling value propositions and successful commercialization." "It is an honor to lead the development of ANPD001," said Dr. Johnson-Pratt. "With iPSC-derived cell therapies, we have an opportunity to bring a novel approach to patients and the medical field, representing a leap forward in the personalized medicine space. I am excited to join this experienced and committed team to investigate how cell replacement therapies can impact the lives of people with Parkinson's disease, a challenging degenerative condition and the second most common neurological disorder after Alzheimer's disease." A senior drug development, clinical and commercial expert, Lisa has successfully led programs across the entire product life cycle, including in medical affairs, clinical development, product development, portfolio planning and new product strategy for organizations from small biotechs to large pharmaceutical companies, including as the Global Dermatology Portfolio Leader, for Merck, head of Global Commercial Pharma Centers of Excellence and head of Early Pipeline Commercial Strategy for GSK, and the head of New Product Strategy for Akcea Therapeutics and Ionis Pharmaceuticals. Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery. Dr. Johnson-Pratt received her Bachelor of Science and Doctor of Medicine degrees from Howard University, with further post-doctoral training in Internal Medicine, Clinical Pharmacology and Pharmaceutical Medicine. About ANPD001 About Aspen Neuroscience Aspen?combines stem cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company has developed a best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing and QC. For more information and important updates, please visit?https://www.aspenneuroscience.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-lisa-johnson-pratt-joins-aspen-neuroscience-as-senior-vice-president-therapeutic-program-lead-302061398.html SOURCE Aspen Neuroscience, Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |